Ost-müük Caribou Biosciences, Inc. - CRBU CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.05 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024874% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.002651% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 5.11 |
| Avatud* | 5.08 |
| Aastane muutus* | -44.96% |
| Päeva ulatus* | 5 - 5.3 |
| 52 nädala ulatus | 4.12-13.19 |
| Keskmine maht (10 päeva) | 515.24K |
| Keskmine maht (3 kuud) | 9.90M |
| Turukapitalisatsioon | 325.50M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 61.30M |
| Tulu | 13.85M |
| EPS | -1.63 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2023 | 5.30 | 0.19 | 3.72% | 5.11 | 5.30 | 4.98 |
| Mar 30, 2023 | 5.11 | -0.04 | -0.78% | 5.15 | 5.25 | 4.90 |
| Mar 29, 2023 | 5.13 | 0.34 | 7.10% | 4.79 | 5.18 | 4.67 |
| Mar 28, 2023 | 4.69 | 0.03 | 0.64% | 4.66 | 4.87 | 4.54 |
| Mar 27, 2023 | 4.68 | 0.06 | 1.30% | 4.62 | 4.78 | 4.49 |
| Mar 24, 2023 | 4.62 | 0.38 | 8.96% | 4.24 | 4.69 | 4.18 |
| Mar 23, 2023 | 4.26 | -0.11 | -2.52% | 4.37 | 4.43 | 4.10 |
| Mar 22, 2023 | 4.32 | -0.43 | -9.05% | 4.75 | 4.75 | 4.31 |
| Mar 21, 2023 | 4.79 | -0.08 | -1.64% | 4.87 | 4.90 | 4.74 |
| Mar 20, 2023 | 4.85 | -0.04 | -0.82% | 4.89 | 4.91 | 4.69 |
| Mar 17, 2023 | 4.91 | -0.02 | -0.41% | 4.93 | 5.02 | 4.80 |
| Mar 16, 2023 | 5.02 | -0.07 | -1.38% | 5.09 | 5.15 | 4.91 |
| Mar 15, 2023 | 5.15 | 0.10 | 1.98% | 5.05 | 5.25 | 5.02 |
| Mar 14, 2023 | 5.18 | -0.25 | -4.60% | 5.43 | 5.51 | 5.10 |
| Mar 13, 2023 | 5.30 | 0.25 | 4.95% | 5.05 | 5.34 | 5.02 |
| Mar 10, 2023 | 5.14 | -0.29 | -5.34% | 5.43 | 5.48 | 4.93 |
| Mar 9, 2023 | 5.48 | -0.35 | -6.00% | 5.83 | 5.85 | 5.33 |
| Mar 8, 2023 | 5.85 | 0.02 | 0.34% | 5.83 | 5.92 | 5.75 |
| Mar 7, 2023 | 5.86 | 0.03 | 0.51% | 5.83 | 6.04 | 5.70 |
| Mar 6, 2023 | 5.77 | -0.32 | -5.25% | 6.09 | 6.09 | 5.54 |
Caribou Biosciences, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Kogutulu | 13.851 | 9.598 | 12.361 | 5.788 |
| Tulu | 13.851 | 9.598 | 12.361 | 5.788 |
| Kogu tegevuskulu | 120.25 | 74.993 | 48.485 | 40.093 |
| Müük/Üldine/admin kulud, kokku | 38.02 | 24.322 | 14.06 | 16.458 |
| Uuringud ja arendus | 82.23 | 52.255 | 34.425 | 23.635 |
| Tulud majandustegevusest | -106.399 | -65.395 | -36.124 | -34.305 |
| Intressitulud (kulu), muud tulud, neto | -0.133 | 0.14 | -0.517 | 3.337 |
| Muud, neto | 7.181 | -1.347 | 0.514 | 0 |
| Netotulu enne makse | -99.351 | -66.602 | -36.127 | -30.968 |
| Netotulu pärast makse | -99.421 | -66.923 | -34.308 | -23.431 |
| Netotulu enne erikulusid | -99.421 | -66.923 | -34.308 | -23.431 |
| Netotulu | -99.421 | -66.923 | -34.308 | -23.431 |
| Arvestatav tulu, v a erikulud | -99.421 | -66.923 | -34.308 | -23.431 |
| Arvestatav tulu, koos erikuludega | -99.421 | -66.923 | -34.308 | -23.431 |
| Jaotamisele kuuluv netotulu | -99.421 | -66.923 | -34.308 | -23.431 |
| Keskmine jaotamisele kuuluv aktsia kohta | 60.8011 | 60.2632 | 56.7092 | 56.7092 |
| Jaotatav EPS, v a erakorralised kulud | -1.63518 | -1.11051 | -0.60498 | -0.41318 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -1.63518 | -1.1276 | -0.60498 | -0.41318 |
| Ootamatud kulutused (tulu) | 0 | -1.584 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 3.692 | 3.303 | 4.192 | 2.664 | 2.559 |
| Tulu | 3.692 | 3.303 | 4.192 | 2.664 | 2.559 |
| Kogu tegevuskulu | 34.27 | 29.84 | 32.623 | 23.517 | 22.964 |
| Müük/Üldine/admin kulud, kokku | 8.534 | 9.849 | 10.044 | 9.593 | 7.853 |
| Uuringud ja arendus | 25.736 | 19.991 | 22.579 | 13.924 | 15.111 |
| Tulud majandustegevusest | -30.578 | -26.537 | -28.431 | -20.853 | -20.405 |
| Intressitulud (kulu), muud tulud, neto | -0.06 | 0.031 | -0.016 | 0.163 | 0.076 |
| Muud, neto | 3.719 | -0.141 | 1.75 | 1.602 | 2.171 |
| Netotulu enne makse | -26.919 | -26.647 | -26.697 | -19.088 | -18.158 |
| Netotulu pärast makse | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Netotulu enne erikulusid | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Netotulu | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Arvestatav tulu, v a erikulud | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Arvestatav tulu, koos erikuludega | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Jaotamisele kuuluv netotulu | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Keskmine jaotamisele kuuluv aktsia kohta | 61.01 | 60.8869 | 60.7577 | 60.5462 | 60.2632 |
| Jaotatav EPS, v a erakorralised kulud | -0.44237 | -0.43765 | -0.4394 | -0.31526 | -0.30664 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.44237 | -0.43765 | -0.4394 | -0.31526 | -0.30664 |
| Ootamatud kulutused (tulu) | 0 | 0 | 0 | 0 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Käibevarad kokku | 391.192 | 24.306 | 57.008 |
| Raha ja lühiajalised investeeringud | 375.832 | 15.953 | 49.471 |
| Raha ja ekvivalendid | 240.42 | 15.953 | 41.07 |
| Lühiajalised investeeringud | 135.412 | 0 | 8.401 |
| Laekumata arved, neto | 8.124 | 5.16 | 3.982 |
| Accounts Receivable - Trade, Net | 2.641 | 1.478 | 0.841 |
| Prepaid Expenses | 6.565 | 2.433 | 3.182 |
| Other Current Assets, Total | 0.671 | 0.76 | 0.373 |
| Total Assets | 442.356 | 36.046 | 61.933 |
| Property/Plant/Equipment, Total - Net | 4.887 | 3.502 | 4.332 |
| Property/Plant/Equipment, Total - Gross | 8.964 | 6.598 | 6.59 |
| Accumulated Depreciation, Total | -4.077 | -3.096 | -2.258 |
| Long Term Investments | 45.302 | 7.626 | 0 |
| Other Long Term Assets, Total | 0.975 | 0.612 | 0.593 |
| Total Current Liabilities | 25.829 | 12.389 | 10.078 |
| Accounts Payable | 3.99 | 2.601 | 2.537 |
| Accrued Expenses | 12.089 | 8.151 | 5.653 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.654 | 0 |
| Other Current Liabilities, Total | 9.75 | 0.983 | 1.888 |
| Total Liabilities | 54.531 | 18.16 | 13.147 |
| Total Long Term Debt | 0 | 0.924 | 0 |
| Long Term Debt | 0 | 0.924 | 0 |
| Deferred Income Tax | 0.476 | 0.155 | 0.65 |
| Other Liabilities, Total | 28.226 | 4.692 | 2.419 |
| Total Equity | 387.825 | 17.886 | 48.786 |
| Preferred Stock - Non Redeemable, Net | 0 | 41.323 | 41.323 |
| Common Stock | 0.006 | 0.001 | 0.001 |
| Additional Paid-In Capital | 485.748 | 7.433 | 4.025 |
| Retained Earnings (Accumulated Deficit) | -97.794 | -30.871 | 3.437 |
| Total Liabilities & Shareholders’ Equity | 442.356 | 36.046 | 61.933 |
| Total Common Shares Outstanding | 60.2632 | 56.7092 | 56.7092 |
| Other Equity, Total | -0.135 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 368.01 | 391.192 | 449.047 | 142.967 | 155.925 |
| Raha ja lühiajalised investeeringud | 353.731 | 375.832 | 435.31 | 129.524 | 145.924 |
| Raha ja ekvivalendid | 147.63 | 240.42 | 435.31 | 129.524 | 145.924 |
| Laekumata arved, neto | 6.037 | 8.124 | 7.785 | 8.407 | 5.825 |
| Accounts Receivable - Trade, Net | 1.868 | 2.641 | 2.431 | 0.832 | 1.049 |
| Prepaid Expenses | 7.276 | 6.565 | 5.189 | 3.759 | 3.096 |
| Other Current Assets, Total | 0.966 | 0.671 | 0.763 | 1.277 | 1.08 |
| Total Assets | 445.997 | 442.356 | 461.96 | 158.397 | 167.965 |
| Property/Plant/Equipment, Total - Net | 31.765 | 4.887 | 4.477 | 4.408 | 3.38 |
| Property/Plant/Equipment, Total - Gross | 36.15 | 8.964 | 8.282 | 7.952 | 6.695 |
| Accumulated Depreciation, Total | -4.385 | -4.077 | -3.805 | -3.544 | -3.315 |
| Long Term Investments | 44.758 | 45.302 | 7.626 | 7.626 | 7.626 |
| Other Long Term Assets, Total | 1.464 | 0.975 | 0.81 | 3.396 | 1.034 |
| Total Current Liabilities | 26.667 | 25.829 | 26.158 | 26.007 | 22.21 |
| Accounts Payable | 1.814 | 3.99 | 3.482 | 4.029 | 3.117 |
| Accrued Expenses | 11.215 | 12.089 | 12.288 | 11.034 | 10.929 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0.655 | |
| Other Current Liabilities, Total | 13.638 | 9.75 | 10.388 | 10.944 | 7.509 |
| Total Liabilities | 74.2 | 54.531 | 57.559 | 55.938 | 53.504 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0.926 |
| Long Term Debt | 0 | 0 | 0 | 0.926 | |
| Deferred Income Tax | 0.476 | 0.476 | 0.155 | 0.155 | 0.155 |
| Other Liabilities, Total | 47.057 | 28.226 | 31.246 | 29.776 | 30.213 |
| Total Equity | 371.797 | 387.825 | 404.401 | 102.459 | 114.461 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 150.15 | 150.15 |
| Common Stock | 0.006 | 0.006 | 0.006 | 0.001 | 0.001 |
| Additional Paid-In Capital | 489.762 | 485.748 | 483.71 | 10.649 | 8.34 |
| Retained Earnings (Accumulated Deficit) | -116.882 | -97.794 | -79.315 | -58.341 | -44.03 |
| Total Liabilities & Shareholders’ Equity | 445.997 | 442.356 | 461.96 | 158.397 | 167.965 |
| Total Common Shares Outstanding | 60.6896 | 60.2632 | 60.0213 | 59.9708 | 56.7092 |
| Lühiajalised investeeringud | 206.101 | 135.412 | |||
| Other Equity, Total | -1.089 | -0.135 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Netotulu/algväärtus | -99.421 | -66.923 | -34.308 | -23.431 |
| Raha majandustegevusest | -90.966 | -32.519 | -33.215 | -32.006 |
| Raha majandustegevusest | 1.622 | 0.984 | 0.9 | 0.751 |
| Mittelikviidsed varad | 11.037 | 4.353 | 0.016 | -1.059 |
| Cash Taxes Paid | 0 | 0.011 | 0.021 | 1.809 |
| Muutused tööjõus | -4.204 | 29.067 | 0.177 | -8.267 |
| Tulu investeeringutelt | -93.249 | -176.397 | 6.363 | 27.233 |
| Kapitalikulutused | -6.454 | -2.121 | -0.317 | -0.884 |
| Muud rahavood investeeringutelt, kokku | -86.795 | -174.276 | 6.68 | 28.117 |
| Rahavood investeeringutelt | 2.133 | 433.429 | 1.735 | 0.172 |
| Aktsiate emiteerimine (tagasiost), neto | 2.133 | 432.398 | 1.848 | 0.217 |
| Laenu väljastamine (kustutamine), neto | 0 | 1.031 | -0.113 | -0.045 |
| Rahaline kogumuutus | -182.082 | 224.513 | -25.117 | -4.601 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -99.421 | -72.432 | -45.785 | -19.088 | -66.923 |
| Cash From Operating Activities | -90.966 | -65.922 | -43.546 | -21.673 | -32.519 |
| Cash From Operating Activities | 1.622 | 1.116 | 0.666 | 0.308 | 0.984 |
| Non-Cash Items | 11.037 | 9.47 | 4.942 | 2.215 | 4.353 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0.011 |
| Cash Interest Paid | 0 | ||||
| Changes in Working Capital | -4.204 | -4.076 | -3.369 | -5.108 | 29.067 |
| Cash From Investing Activities | -93.249 | -94.419 | -86.08 | -72.107 | -176.397 |
| Capital Expenditures | -6.454 | -4.697 | -3.343 | -0.723 | -2.121 |
| Other Investing Cash Flow Items, Total | -86.795 | -89.722 | -82.737 | -71.384 | -174.276 |
| Cash From Financing Activities | 2.133 | 2.006 | 1.352 | 0.99 | 433.429 |
| Issuance (Retirement) of Stock, Net | 2.133 | 2.006 | 1.352 | 0.99 | 432.398 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | 1.031 |
| Net Change in Cash | -182.082 | -158.335 | -128.274 | -92.79 | 224.513 |
| Financing Cash Flow Items | 0 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| PFM Health Sciences, LP | Hedge Fund | 7.2754 | 4459783 | -1540217 | 2022-12-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.6832 | 4096777 | 277588 | 2022-12-31 | LOW |
| Haurwitz (Rachel E. Ph.D.) | Individual Investor | 5.5129 | 3379395 | 10000 | 2023-03-20 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.2184 | 3198893 | 803423 | 2022-12-31 | LOW |
| Avidity Partners Management LP | Hedge Fund | 4.7025 | 2882600 | -290000 | 2022-12-31 | HIGH |
| Rokos Capital Management LLP | Hedge Fund | 4.4831 | 2748139 | 840630 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1939 | 2570827 | 26789 | 2022-12-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.1662 | 2553878 | -737020 | 2022-12-31 | LOW |
| Elmwood Wealth Management, INC. | Investment Advisor | 3.8569 | 2364240 | 0 | 2022-12-31 | LOW |
| EIDP Inc | Corporation | 3.3573 | 2058000 | -1093311 | 2022-05-31 | MED |
| BofA Global Research (US) | Research Firm | 3.008 | 1843902 | 1668395 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.3541 | 1443046 | -547 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.982 | 1214933 | 30615 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6819 | 1030987 | 45617 | 2022-12-31 | LOW |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 1.4575 | 893424 | -138016 | 2022-12-31 | LOW |
| Fidelity International | Investment Advisor | 1.404 | 860666 | 0 | 2022-12-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3944 | 854738 | 55247 | 2022-12-31 | HIGH |
| Maverick Capital, Ltd. | Hedge Fund | 1.0645 | 652542 | 0 | 2022-12-31 | MED |
| Tekla Capital Management LLC | Investment Advisor | 0.9252 | 567147 | 0 | 2022-12-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.9215 | 564855 | -1059 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Caribou Biosciences, Inc. Company profile
Ettevõttest Caribou Biosciences, Inc.
Caribou Biosciences, Inc. on Ameerika Ühendriikides asuv kliinilise faasi biotehnoloogia ettevõte. Ettevõte kasutab CRISPR-genoomi redigeerimist, et avastada ja arendada immuunrakupõhiseid ravimeid vähktõve vastu. Ettevõte keskendub genoomi redigeeritud CAR-T rakkude ja looduslike tapjarakkude (NK) ravimeetodite väljatöötamisele erinevate kasvajatüüpide jaoks. Samuti pakub ta litsentse oma CRISPR-Cas9 aluspõhisele intellektuaalomandile mitmes valdkonnas, sealhulgas uurimisvahendite, sisemise teadustegevuse, diagnostika ja tööstusliku biotehnoloogia valdkonnas. Ettevõtte tooteprogrammi kuuluvad CB-010, CB-011, CB-012 ja CB-020.
| Industry: | Biotechnology & Medical Research (NEC) |
2929 7Th Street, Ste 120
BERKELEY
CALIFORNIA 94710
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com